OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
June 13, 2022
Precision BioSciences has released clinical trial data on CAR T therapy candidates PBCAR0191, PBCAR19B, and PBCAR269A.
June 03, 2022
Thermo Fisher Scientific and Qatar Genome Program will use custom genotyping arrays to accelerate genomic research in Qatar.
Putting the patient at the forefront of drug development is essential, particularly to ensure medication compliance is optimized.
The right processes used with the right excipient combinations address evolving formulation needs.
Collecting relevant data, planning ahead, and communicating with regulatory bodies in pre-IND meeting programs can help companies to avoid roadblocks in IND applications.
June 02, 2022
The inaugural Connect in Pharma event will take place on 14 and 15 September in Geneva, Switzerland.
May 26, 2022
Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.
Lubrizol has launched Apisolex technology to improve solubility and simplify the manufacturing of parenteral drug products.
May 24, 2022
A new initiative aims to speed the approval of and access to new drugs for young patients around the world, while limiting the number of children needed for testing in clinical trials.
Investment has been made into a new science hub at the University of Edinburgh for the development of treatments for lung infections and future pandemics.